Skip to content

CareDx

US · CDNA #2371 by market cap Listed 1970
70.00 -1.92 -2.67%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 8.75 Expensive vs history 99th percentile
5-year average 3.09 · #33 of 41 in Diagnostics & Research
P/E ratio 32.86 Expensive vs history 99th percentile
5-year average -19.14 · forward 141.72 · #8 of 20 in Diagnostics & Research
P/S ratio 8.23 Expensive vs history 97th percentile
5-year average 3.40 · forward 7.37 · #32 of 44 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
CareDx (CDNA) 3.68B 29.54 7.87 0.00%
Thermo Fisher Scientific (TMO) 248.08B 35.31 4.53 0.27%
Danaher (DHR) 155.03B 36.12 2.89 0.69%
IDEXX Laboratories Inc (IDXX) 53.28B 45.57 28.50 0.00%
Agilent Technologies (A) 48.04B 33.61 6.52 0.59%
Waters (WAT) 43.29B 184.29 2.83 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★☆☆☆ Fair value63.46 Economic moatNarrow UncertaintyHigh

Trading 9.3% above Morningstar's fair value estimate.

Fair value

CareDx Inc earns a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 23% premium over our quantitative fair value estimate of $63.46 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's lack of profitability decreases our valuation estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of 1.7%, which falls in the bottom 40% globally. The earnings generated by the company relative to its share price is concerning, which contributes to our view that shares are overvalued.

The company's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 11.3%, a core component of valuation, falls in the bottom 10% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.

Economic moat

The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:25 · For reference only, not investment advice and not tailored to your situation.

CareDx discussion 0 comments

Add a comment